Compositions and methods using Cas9 with enhanced spacer acquisition function

US11377645B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11377645-B2
Application numberUS-201716470195-A
CountryUS
Kind codeB2
Filing dateDec 18, 2017
Priority dateDec 16, 2016
Publication dateJul 5, 2022
Grant dateJul 5, 2022

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Provided are Cas9 enzymes that have mutations that enhance their properties, relative to un-mutated Cas9. The altered Cas9 enzymes exhibit i) an increased rate of spacer acquisition, or ii) increased cleavage efficiency of targets with NAG PAMs, or a combination of i) and ii). The altered Cas9 enzymes comprise an amino acid substitution of 1473 and K500 in a Streptococcus pyogenes or similar Cas9 enzyme. Also provided are polynucleotides, including expression vectors that encode the Cas9 enzymes, cells that contain the polynucleotides, and methods of making and using such cells. The disclosure includes tagging, or labelling bacteria, and for enhancing phage acquired immunity in bacteria, such as those used in industrial processes, including the food and beverage industry, such as the dairy industry. The food products are also included.

First claim

Opening claim text (preview).

What is claimed is: 1. An expression vector encoding a Cas9 enzyme comprising a substitution, wherein the substitution is of at least one of the following amino acids: I473 and K500 in SEQ ID NO:1, and wherein relative to a control the Cas9 enzyme exhibits at least one of: i) increased rate of spacer acquisition, or ii) increased cleavage efficiency of targets with NAG protospacer adjacent motifs (PAMs), wherein the control comprises a rate of spacer acquisition, or increased cleavage efficiency of targets with NAG PAMs, produced by a Cas9 enzyme comprising the sequence of SEQ ID NO:1. 2. The expression vector of claim 1 , wherein the Cas9 enzyme is a Streptococcus pyogenes Cas9 enzyme. 3. The expression vector of claim 1 , wherein the substitution comprises I473F. 4. The expression vector of claim 1 , wherein the substitution comprises I473F and K500I. 5. Bacteria comprising an expression vector of claim 1 . 6. A method of making modified bacteria comprising introducing into the bacteria an expression vector of claim 4 . 7. A method comprising contacting bacteria of claim 5 with one or more bacteriophage such that at least one spacer sequence in the genome of the bacteriophage is acquired by the bacteria. 8. The method of claim 7 , wherein the bacteria are contacted with a plurality of distinct bacteriophage, and wherein the bacteria acquire a plurality of distinct spacer sequences from the plurality of the bacteriophage, and wherein the number of distinct spacers in the plurality is greater that a control value, and/or the distinct spacers in the plurality are acquired more quickly than for a control value, and wherein the control value comprises a number of distinct spacers, or a rate at which spacers are acquired, obtained by contacting bacteria that express a Cas9 enzyme comprising the sequence of SEQ ID NO:1 with a plurality of distinct bacteriophage. 9. The method of claim 7 , wherein the bacteriophage are obtained from a bacterial culture used to produce a food product or a beverage. 10. The method of claim 9 , wherein the food product comprises a dairy product. 11. A food product comprising bacteria of claim 5 . 12. The food product of claim 11 , wherein the food product comprises a dairy product. 13. A method for labeling bacteria with one or more spacer sequences, the method comprising introducing into the bacteria an expression vector of claim 1 , and introducing into the bacteria a polynucleotide comprising at least one spacer sequence. 14. The method of claim 13 , further comprising determining the sequence of at least one spacer sequence from bacteria that acquired the spacer sequence. 15. A Cas9 enzyme comprising an amino acid substitution, wherein the amino acid substitution is of at least one of the following amino acids: I473 and K500 in SEQ ID NO:1, and wherein relative to a control the Cas9 enzyme exhibits at least one of: i) increased rate of spacer acquisition, or ii) increased cleavage efficiency of targets with NAG protospacer adjacent motifs (PAMs), wherein the control comprises a rate of spacer acquisition, or increased cleavage efficiency of targets with NAG PAMs, produced by a Cas9 enzyme comprising the sequence of SEQ ID NO:1. 16. The Cas9 enzyme of claim 15 , wherein the Cas9 enzyme is a Streptococcus pyogenes Cas9 enzyme.

Assignees

Inventors

Classifications

  • Preparation of wine or sparkling wine · CPC title

  • from bacteria · CPC title

  • using only microorganisms of the genus lactobacteriaceae; Yoghurt (A23C9/13 takes precedence) · CPC title

  • involving clustered regularly interspaced short palindromic repeats [CRISPR] · CPC title

  • Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11377645B2 cover?
Provided are Cas9 enzymes that have mutations that enhance their properties, relative to un-mutated Cas9. The altered Cas9 enzymes exhibit i) an increased rate of spacer acquisition, or ii) increased cleavage efficiency of targets with NAG PAMs, or a combination of i) and ii). The altered Cas9 enzymes comprise an amino acid substitution of 1473 and K500 in a Streptococcus pyogenes or similar Ca…
Who is the assignee on this patent?
Univ Rockefeller
What technology area does this patent fall under?
Primary CPC classification C12N9/22. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jul 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).